◎ Sugi Atlas

Atlas / Disease / Neonatal abstinence syndrome

Neonatal abstinence syndrome

disease
On this page

Also known as NASneonatal narcotic withdrawal syndromeneonatal withdrawal

Summary

Neonatal abstinence syndrome (MONDO:0005566) is a disease with 58 GWAS associations across 3 studies and 65 clinical trials. Top therapeutic interventions include clonidine, methadone, and morphine. A subtype of substance withdrawal syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • GWAS associations: 58
  • Clinical trials: 65

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameneonatal abstinence syndrome
Mondo IDMONDO:0005566
EFOEFO:0005799
MeSHD009357
DOIDDOID:9828
ICD-10-CMP96.1
NCITC87101
SNOMED CT414819007
UMLSC0027609
MedGen10207
Is cancer (heuristic)no

Also known as: NAS · neonatal narcotic withdrawal syndrome · neonatal withdrawal

Data availability: 58 GWAS associations (3 studies).

Disease family

This is a subtype of substance withdrawal syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › substance withdrawal syndrome › neonatal abstinence syndrome

Related subtypes (2): alcohol withdrawal, baclofen withdrawal syndrome

Genetics & variants

GWAS landscape

58 GWAS associations across 3 studies. Top hits map to 29 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs102775012e-08LINC02889 - SNX13?1.47
rs733137864e-08LINC02889 - SNX13?1.45
rs15660025e-08RN7SL366P - C6orf118?0.79
rs47629097e-07TCP1P3 - LINC02468?0.91
rs7066179e-07DLEU1?1.43
rs603449999e-07C1QL3 - RSU1?3.2
rs112606032e-06LINC01342?0.8
rs340200752e-06RPSAP53 - LINC00364?1.1
rs71510302e-06GPATCH2L - ESRRB?0.78
rs1439940922e-06RN7SL596P - SPINDOC?0.99
rs22365372e-06LINC01344?2.38
rs37956462e-06NOS1AP?1.56
rs9816103e-06LINC03000?0.74
rs6183683e-06ZDHHC14?0.65
rs42347453e-06PPP2R2C?0.87
rs617663523e-06LINC01342 - MIR200B?0.84
rs619814993e-06RPL23AP71 - EAPP?0.69
rs732486833e-06USP46-DT - DANCR?2.34
rs1137848213e-06C10orf90?3.46
rs29523033e-06FAM20A?1.9
rs283665653e-06MRPS33P3 - RPF2P2?1.81
rs619301884e-06SLC22A25?2.04
rs98097504e-06KALRN?0.69
rs118582854e-06SLC27A2?1.62
rs728332284e-06RPS26P39 - LINC02641?1.88
rs126152475e-06LINC01122?0.7
rs49052235e-06SERPINA5?0.92
rs19625245e-06RNF38?0.79
rs118847635e-06CMKLR2-AS?3.77
rs131720006e-06TNFAIP8?0.67

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90134523Bibi S20222310Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome.
GCST90134522Bibi S2022590Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome.
GCST90134524Bibi S2022590Polygenic risk scores and the need for pharmacotherapy in neonatal abstinence syndrome.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR2
Tier 3: regulatory0
Tier 4: intronic/intergenic47

MAF distribution

BucketVariants
common (>=0.05)50
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
intron_variant28
intergenic_variant16
non_coding_transcript_exon_variant3
5_prime_UTR_variant1
missense_variant1
3_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs10277501717669531G>A,T0.05intergenic_variantLINC02889 - SNX132e-08Tier 4: intronic/intergenic
rs73313786717667171G>A0.05intergenic_variantLINC02889 - SNX134e-08Tier 4: intronic/intergenic
rs15660026164666790C>T0.05intergenic_variantRN7SL366P - C6orf1185e-08Tier 4: intronic/intergenic
rs47629091219982746G>A,T0.05intron_variantTCP1P3 - LINC024687e-07Tier 4: intronic/intergenic
rs7066171350129049C>A,G,T0.05intron_variantDLEU19e-07Tier 4: intronic/intergenic
rs603449991016544523TAAAAAAAAAAA>T,TA,TAA,TAAA,TAAAA,TAAAAA,TAAAAAA,TAAAAAAA,TAAAAAAAA,TAAAAAAAAA,TAAAAAAAAAA,TAAAAAAAAAAAA,TAAAAAAAAAAAAA,TAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA,TAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA0.05intron_variantC1QL3 - RSU19e-07Tier 4: intronic/intergenic
rs1126060311143818T>C,G0.05non_coding_transcript_exon_variantLINC013422e-06Tier 4: intronic/intergenic
rs340200751367325974G>A,C0.05intron_variantRPSAP53 - LINC003642e-06Tier 4: intronic/intergenic
rs71510301476273281G>C,T0.05intron_variantGPATCH2L - ESRRB2e-06Tier 4: intronic/intergenic
rs1439940921163803842T>C0.05intron_variantRN7SL596P - SPINDOC2e-06Tier 4: intronic/intergenic
rs22365371182089820G>A0.05intron_variantLINC013442e-06Tier 4: intronic/intergenic
rs37956461162167234G>A0.05intron_variantNOS1AP2e-06Tier 4: intronic/intergenic
rs9816105165104150T>A,C,G0.05intron_variantLINC030003e-06Tier 4: intronic/intergenic
rs6183686157657684G>A,C0.05intron_variantZDHHC143e-06Tier 4: intronic/intergenic
rs423474546477966T>C0.05intron_variantPPP2R2C3e-06Tier 4: intronic/intergenic
rs6176635211150799T>A,C,G0.05intergenic_variantLINC01342 - MIR200B3e-06Tier 4: intronic/intergenic
rs619814991434493842A>G0.05intergenic_variantRPL23AP71 - EAPP3e-06Tier 4: intronic/intergenic
rs73248683452699076A>T0.05intergenic_variantUSP46-DT - DANCR3e-06Tier 4: intronic/intergenic
rs11378482110126747567A>G0.05intergenic_variantC10orf903e-06Tier 4: intronic/intergenic
rs29523031768590001A>C,G,T0.05intron_variantFAM20A3e-06Tier 4: intronic/intergenic
rs283665654115468815G>A0.05intergenic_variantMRPS33P3 - RPF2P23e-06Tier 4: intronic/intergenic
rs619301881163238935G>A0.055_prime_UTR_variantSLC22A254e-06Tier 2: splice/UTR
rs98097503124410510T>A,G0.05intron_variantKALRN4e-06Tier 4: intronic/intergenic
rs118582851550196901C>T0.05intron_variantSLC27A24e-06Tier 4: intronic/intergenic
rs7283322810123295447G>C0.05intergenic_variantRPS26P39 - LINC026414e-06Tier 4: intronic/intergenic
rs12615247258960072A>G,T0.05intron_variantLINC011225e-06Tier 4: intronic/intergenic
rs49052231494570686A>C,G,T0.05intron_variantSERPINA55e-06Tier 4: intronic/intergenic
rs1962524936485205A>C,G,T0.05intergenic_variantRNF385e-06Tier 4: intronic/intergenic
rs118847632206246382T>C0.05intron_variantCMKLR2-AS5e-06Tier 4: intronic/intergenic
rs131720005119278437G>C0.05intron_variantTNFAIP86e-06Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

9 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
BuprenorphinePhase 3
ChamomilePhase 3
ChlorpromazinePhase 3
ClonidinePhase 3
Lavender OilPhase 3
MorphinePhase 3
PhenobarbitalPhase 3
MethadonePhase 2
Sodium ChloridePhase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 65.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified41
PHASE47
PHASE36
PHASE26
PHASE2/PHASE32
PHASE12
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03092011PHASE4ACTIVE_NOT_RECRUITINGTreatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
NCT01723722PHASE4COMPLETEDTreatment of Neonatal Abstinence Syndrome
NCT01734551PHASE4COMPLETEDNAS Treatment - Opiate Versus Non-Opiate
NCT01804075PHASE4COMPLETEDComparison Between Methadone and Morphine for Neonatal Opiate Withdrawal
NCT02851303PHASE4COMPLETEDMorphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
NCT03762317PHASE4TERMINATEDClonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome
NCT04298853PHASE4COMPLETEDOptimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome
NCT01360450PHASE2/PHASE3TERMINATEDClonidine to Treat Iatrogenic-induced Opioid Dependence in Infants
NCT01452789PHASE3COMPLETEDBlinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
NCT01561079PHASE2/PHASE3COMPLETEDFetal and Infant Effects of Maternal Buprenorphine Treatment
NCT01958476PHASE3COMPLETEDImproving Outcomes in Neonatal Abstinence Syndrome
NCT02810782PHASE3COMPLETEDHow to Treat Opiate Withdrawal in Neonates
NCT03097484PHASE3COMPLETEDThe Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels
NCT03396588PHASE3COMPLETEDNon-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain
NCT03918850PHASE3COMPLETEDMedication Treatment for Opioid Use Disorder in Expectant Mothers
NCT00510016PHASE2COMPLETEDClonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome
NCT01708707PHASE2COMPLETEDComparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)
NCT01965704PHASE2COMPLETEDCan Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women
NCT02178189PHASE2COMPLETEDRCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants
NCT03134703PHASE2TERMINATEDMethadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome
NCT03608696PHASE1/PHASE2COMPLETEDBuprenorphine Pharmacometric Open Label Research Study of Drug Exposure
NCT03670160PHASE2COMPLETEDClonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome
NCT00521248PHASE1COMPLETEDBuprenorphine for the Treatment of Neonatal Abstinence Syndrome
NCT01671410PHASE1COMPLETEDBuprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines
NCT03533985Not specifiedRECRUITINGEffect of Music Therapy on Infants With Neonatal Abstinence Syndrome
NCT03997422Not specifiedACTIVE_NOT_RECRUITINGHepatic Energy Fluxes in NASH and NAS Patients
NCT04419857Not specifiedACTIVE_NOT_RECRUITINGA Trial to Determine Weight Gain Benefits of Caloric Supplementation for NAS Infants
NCT04783558Not specifiedACTIVE_NOT_RECRUITINGEffective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
NCT05129020Not specifiedACTIVE_NOT_RECRUITINGNeurostimulation to Improve NOWS Outcomes
NCT05226624Not specifiedRECRUITINGThe Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT Program
NCT05937594Not specifiedRECRUITINGMicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome
NCT06303986Not specifiedENROLLING_BY_INVITATIONStudy to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
NCT06576323Not specifiedRECRUITINGAn Intervention Mapping Approach to Closing the Gap in Maternal OUD and Infant NAS Care (SUPPORT)
NCT00496951Not specifiedCOMPLETEDVagal Tone and Neonatal Abstinence Syndrome
NCT01175668Not specifiedTERMINATEDClonidine for Neonatal Abstinence Syndrome Study
NCT01754324Not specifiedCOMPLETEDThe Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome
NCT01889121Not specifiedCOMPLETEDUtility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers
NCT02062151Not specifiedCOMPLETEDAcupuncture in Neonatal Abstinence Syndrome (NAS) Babies
NCT02182973Not specifiedCOMPLETEDDonor Human Milk in Neonatal Abstinence Syndrome
NCT02334111Not specifiedCOMPLETEDRESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CLONIDINE410
METHADONE47
MORPHINE46
PHENOBARBITAL44
CHLORPROMAZINE43
CHEMBL458922602

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 22

This page pulls from 22 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardbsnpdoidefogenccgwasgwas_studyhgncicd10cmmedgenmeshmimmondomondochildmondoparentncitorphanetsctidumls